A linezolid prior authorization (PA) program could help
among Prime Therapeutics’ 2012 book of business,
1305 Corporate Center Drive, Eagan, MN 55121
(ER) visits in a population exposed to a PA program
during a 60-day follow-up. The average total paid per member for linezolid was $1,192 ($1,332) vs. $2,495 ($1,877) **p** = 0.004 (Table 2).

### Results

#### Study design and inclusion criteria

- This study was retrospective and utilized a cohort study design.
- Members in the “Intervention Group” were those who had a linezolid PA program in a commercially insured population’s baseline member characteristics were compared between the intervention and comparison groups, with
- All pharmacy and medical claims were queried in
- Comparisons between groups were performed
- The Logistic regression model was used to test the difference of hospitalization/ER visit between the intervention and comparison groups, with
- Log odds ratio (OR) with 95% confidence interval (CI); confidence interval (CI) that do not cross 1.0 indicate a difference (p < 0.05)

#### Study design and inclusion criteria

- This study was retrospective and utilized a cohort study design.
- Members in the “Intervention Group” were those who had a linezolid PA program in a commercially insured population’s baseline member characteristics were compared between the intervention and comparison groups, with
- All pharmacy and medical claims were queried in
- Comparisons between groups were performed
- The Logistic regression model was used to test the difference of hospitalization/ER visit between the intervention and comparison groups, with
- Log odds ratio (OR) with 95% confidence interval (CI); confidence interval (CI) that do not cross 1.0 indicate a difference (p < 0.05)

#### Study design and inclusion criteria

- This study was retrospective and utilized a cohort study design.
- Members in the “Intervention Group” were those who had a linezolid PA program in a commercially insured population’s baseline member characteristics were compared between the intervention and comparison groups, with
- All pharmacy and medical claims were queried in
- Comparisons between groups were performed
- The Logistic regression model was used to test the difference of hospitalization/ER visit between the intervention and comparison groups, with
- Log odds ratio (OR) with 95% confidence interval (CI); confidence interval (CI) that do not cross 1.0 indicate a difference (p < 0.05)

#### Study design and inclusion criteria

- This study was retrospective and utilized a cohort study design.
- Members in the “Intervention Group” were those who had a linezolid PA program in a commercially insured population’s baseline member characteristics were compared between the intervention and comparison groups, with
- All pharmacy and medical claims were queried in
- Comparisons between groups were performed
- The Logistic regression model was used to test the difference of hospitalization/ER visit between the intervention and comparison groups, with
- Log odds ratio (OR) with 95% confidence interval (CI); confidence interval (CI) that do not cross 1.0 indicate a difference (p < 0.05)

#### Study design and inclusion criteria

- This study was retrospective and utilized a cohort study design.
- Members in the “Intervention Group” were those who had a linezolid PA program in a commercially insured population’s baseline member characteristics were compared between the intervention and comparison groups, with
- All pharmacy and medical claims were queried in
- Comparisons between groups were performed
- The Logistic regression model was used to test the difference of hospitalization/ER visit between the intervention and comparison groups, with
- Log odds ratio (OR) with 95% confidence interval (CI); confidence interval (CI) that do not cross 1.0 indicate a difference (p < 0.05)

#### Study design and inclusion criteria

- This study was retrospective and utilized a cohort study design.
- Members in the “Intervention Group” were those who had a linezolid PA program in a commercially insured population’s baseline member characteristics were compared between the intervention and comparison groups, with
- All pharmacy and medical claims were queried in
- Comparisons between groups were performed
- The Logistic regression model was used to test the difference of hospitalization/ER visit between the intervention and comparison groups, with
- Log odds ratio (OR) with 95% confidence interval (CI); confidence interval (CI) that do not cross 1.0 indicate a difference (p < 0.05)

#### Study design and inclusion criteria

- This study was retrospective and utilized a cohort study design.
- Members in the “Intervention Group” were those who had a linezolid PA program in a commercially insured population’s baseline member characteristics were compared between the intervention and comparison groups, with
- All pharmacy and medical claims were queried in
- Comparisons between groups were performed
- The Logistic regression model was used to test the difference of hospitalization/ER visit between the intervention and comparison groups, with
- Log odds ratio (OR) with 95% confidence interval (CI); confidence interval (CI) that do not cross 1.0 indicate a difference (p < 0.05)

#### Study design and inclusion criteria

- This study was retrospective and utilized a cohort study design.
- Members in the “Intervention Group” were those who had a linezolid PA program in a commercially insured population’s baseline member characteristics were compared between the intervention and comparison groups, with
- All pharmacy and medical claims were queried in
- Comparisons between groups were performed
- The Logistic regression model was used to test the difference of hospitalization/ER visit between the intervention and comparison groups, with
- Log odds ratio (OR) with 95% confidence interval (CI); confidence interval (CI) that do not cross 1.0 indicate a difference (p < 0.05)